Cabio Biotech (Wuhan) Co (SHSE:688089) ROCE % : 7.46% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cabio Biotech (Wuhan) Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 7.46%.

Cabio Biotech (Wuhan) Co ROCE % Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co ROCE % Chart

Cabio Biotech (Wuhan) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

15.64

12.20

11.21

5.57

6.87

Cabio Biotech (Wuhan) Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															4.58	6.30	7.37	9.29	7.46

Cabio Biotech (Wuhan) Co ROCE % Calculation

Cabio Biotech (Wuhan) Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	100.597	/	( ( (1611.338 - 180.443)	+	(1611.493 - 112.423) )	/ 2 )
	=	100.597	/	( (1430.895	+	1499.07)	/ 2 )
	=	100.597	/	1464.9825
	=	6.87 %

Cabio Biotech (Wuhan) Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	112.72	/	( ( (1611.493 - 112.423)	+	(1617.239 - 95.051) )	/ 2 )
	=	112.72	/	( ( 1499.07	+	1522.188 )	/ 2 )
	=	112.72	/	1510.629
	=	7.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Cabio Biotech (Wuhan) Co (SHSE:688089) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cabio Biotech (Wuhan) Co ROCE % Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabio Biotech (Wuhan) Co (SHSE:688089) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073

Website

http://www.cabio.cn

Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.

Executives

Shang Yun	Core technical personnel
Wang Hua Biao	Directors, senior managers
Geng An Feng	senior management
Du Bin	Director
Yi Hua Rong	senior management
Ma Tao	senior management
Li Xiang Yu	senior management
Wu Yu Jun	Supervisors
Xiao Min	senior management
Wang Zhi Ming	senior management
Lu Shu Huan	Core technical personnel
Yi De Wei	Director

Cabio Biotech (Wuhan) Co (SHSE:688089) Headlines

No Headlines